OpenAI NewsArticle
OpenAI acquires Orchestra Bio
This is a vertical play. OpenAI is not just selling API access anymore, it's building domain expertise and locked-in workflows in biotech. For builders in biopharma: this means OpenAI will have a native advantage in that vertical. For investors: this is how foundation model companies transition from utilities to applications. Expect similar moves from Anthropic and others.